Clinical Trial Search

Primary: Number of Subjects With Single Negative Polymerase Chain Reaction (PCR) Result and 3 Negative Culture Assays — 96.6 percentage of participants

Primary: Change From Baseline in Baroreflex Sensitivity (BRS) at Attainment of Heart Rate Goal — 7.78; 7.92; 3.27; 2.88 millisecond per millimeter of mercury

Primary: Pathologic Complete Response (pCR) Rate — 18 Participants

Primary: Progression-free Survival (PFS), Based on Radiological or Pathologic Assessment — 386; 478 Days — p=0.655

Primary: Colonic Geometric Center at 24 Hours (GC24) Measured by Scintigraphy — 1.96; 1.98; 2.45; 1.84 units on a scale — p=<0.01

Primary: The Percentage of Participants Who Had Experienced Asthma Exacerbation(s) at the End of the Study — 16; 22 percentage of participants

Primary: Pathologic Complete Response — 23 Participants

Primary: Number of Patients Managed With Blood Transfusion — 0; 5 participants

Primary: Total Hip Bone Mineral Density Percent Change From Baseline at Month 12 — 2.2; 0.9 Percentage Change From Baseline — p=<0.0001

Primary: 12 Hour Plasma Interleukin (IL)-6 to IL-10 Ratio — 8.9; 3.8 ratio

Primary: Number of Participants Smoking Daily at 12th Grade — 995; 976 participants

Primary: Change in Endothelial Function (Reactive Hyperemia Peripheral Arterial Tonometry (RH-PAT) Index Score) — 0.06; 0.22 units on a scale — p=0.25

Primary: Number of Patients Managed With Blood Transfusion — 15; 14 participants

Primary: Steps Per Day — 6369; 6063 steps per day — p=0.16

Primary: Progression Free Survival in Patients With Platinum and Taxane Refractory Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Cancer With Bendamustine…